Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India
Shots:
- Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer- metastatic breast cancer and metastatic gastric cancer)
- Marketed as 150mg and 440mg multiple dose vials
- As per Dr. Reddy- it has four biosimilars commercialized in India
Ref: Dr. Reddy Laboratories | Image: Dr Reddy’s
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
